• Facebook
  • Twitter
  • LinkedIn
  • Google +
  • RSS

National Institute for Health and Care Excellence (NICE) - Articles and news items

epr-logo

NICE does not recommend obinutuzumab to treat follicular lymphoma

Industry news / 20 September 2016 / Niamh Louise Marriott, Digital Content Producer

Obinutuzumab with bendamustine is used to treat follicular lymphoma in people who did not respond to, or whose condition has progressed after treatment…

coil-pill-iud

NICE says coil is more effective than pill as emergency contraception

Industry news / 8 September 2016 / Niamh Louise Marriott, Digital Content Producer

The coil is the most effective form of emergency contraception for up to 5 days after unprotected sex or within 5 days of expected ovulation…

roche-skin-cancer-not-effective

NICE says Roche’s skin cancer drug not cost effective

Industry news / 6 September 2016 / Niamh Louise Marriott, Digital Content Producer

The committee agreed the combination offers life extending benefit compared to vemurafenib alone, however compared to alternative treatments it is too expensive. About 1,000 people would have been eligible each year…

prostate-cancer-drug-approved-nhs

NICE recommends Bayer’s prostate cancer drug for routine NHS use

Industry news / 2 September 2016 / Niamh Louise Marriott, Digital Content Producer

NICE has today issued draft final guidance recommending radium-223 dichloride (Xofigo, Bayer) as an option for treating prostate cancer…

cancer drugs

Re-evaluating the Cancer Drugs Fund: Out with the old, in with the new

Blog, Z Homepage promo / 31 August 2016 / Niamh Louise Marriott, Digital Content Producer

In April of this year, NICE started to assess the cost and clinical effectiveness of every drug currently in the old cancer drugs fund…

NHS two cdf pills

NICE approves CDF drugs for routine NHS use

Industry news / 24 August 2016 / National Institute for Health and Care Excellence (NICE)

The National Institute for Health and Care Excellence (NICE) issued final guidance recommending two drugs for routine use within the NHS: Bosutinib (Bosulif, Pfizer) for treating some patients with leukaemia and Pemetrexed (Alimta, Eli Lilly) for treating some patients with lung cancer…

cost-effective cdf pills and money

NICE says Bayer’s liver cancer drug is not cost-effective

Industry news / 24 August 2016 / The National Institute for Health and Care Excellence (NICE)

NICE originally published guidance in 2010 which said that sorafenib was not cost effective but it was then made available through the CDF. NICE is reconsidering sorafenib as part of its programme to appraise drugs that are currently available…

cost effective cancer drug

NICE says Novartis’ and Janssen’s cancer drugs are not cost effective

Industry news / 18 August 2016 / The National Institute for Health and Care Excellence (NICE)

New draft guidance advises that everolimus, for treating advanced breast cancer after endocrine therapy, and ibrutinib, for treating relapsed or refractory mantle cell lymphoma, be removed from the Cancer Drugs Fund for not being cost effective…

Crizotinib lung cancer price drop

NICE recommends Pfizer’s lung cancer drug after price drop

Industry news / 18 August 2016 / The National Institute for Health and Care Excellence (NICE)

When initially reviewed, the committee concluded that the drug was too expensive compared to the current standard of care. Pfizer submitted further evidence, including a new patient access scheme that provided the drug at a lower price alongside revised analyses, which the committee then concluded could now be considered value for money on the NHS…

anti-clotting

NICE recommends thousands to receive £2-a-day anti-clotting drug

Industry news / 15 August 2016 / National Institute for Health and Care Excellence (NICE)

A higher dose of ticagrelor is already recommended for 12 months after a heart attack. Now new draft guidance is recommending it is continued in these people at a lower dose for a further three years to reduce their risk of a further heart attack or stroke…

SMC u turn lifeline

SMC ‘U-turn’ offers lifeline to Scottish skin cancer patients

Industry news / 8 August 2016 / Bristol-Myers Squibb

The SMC initially refused access to nivolumab for Scottish patients, having taken a different view to the National Institute for Health and Care Excellence (NICE), which approved it to treat patients in England and Wales. However, following a review of additional evidence, the SMC decision has been reversed, bringing access in Scotland on par with the rest of the UK…

ankylosing spondylitis featured

NICE recommends secukinumab for people with ankylosing spondylitis

Industry news / 4 August 2016 / National Institute for Health and Care Excellence (NICE)

The National Institute for Health and Care Excellence (NICE) has recommended innovative new drug secukinumab for treating ankylosing spondylitis, a type of arthritis that mainly affects the back….

 

Webinar: Different thermal analysis techniques to measure the glass transitionWATCH NOW
+ +